Luteal Phase Administration of Paroxetine for the Treatment of PMDD
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The efficacy of SSRI use to relieve the symptoms associated with premenstrual dysphoric
disorder has been established. We proposed to test the hypothesis that intermittent treatment
with paroxetine administered during the luteal phase of the menstrual cycle only is more
effective than placebo in improving symptoms of PMDD. This was a double-blind,
placebo-controlled, three-arm parallel group study of patients with PMDD. Menstruating women
18 years of age or older who met criteria for inclusion in the study were randomized to one
of three arms: paroxetine 10mg/day during the luteal phase of the menstrual cycle; paroxetine
20mg/day during the luteal phase of the menstrual cycle; placebo daily during the luteal
phase of the menstrual cycle. The objective was to evaluate the efficacy and safety of
intermittent treatment of paroxetine in women with PMDD.